Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former GSK Exec Steven Skolsky Becomes Trimeris CEO

This article was originally published in The Pink Sheet Daily

Executive Summary

Skolsky succeeds company founder Dani Bolognesi, who will stay on as chief scientific officer. Previously, Skolsky was GlaxoSmithKline senior VP-global commercial strategy.

You may also be interested in...



Trimeris Seeks New President

Trimeris is searching for a successor to President Nixon Ellis, PhD, following a June 2 announcement that he will leave the company by mutual agreement

Bristol To Name New R&D Head Shortly

Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.

Chiron Fluvirin Remediation Plan Design Underway

The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel